Superworth

NovoCure price to book ratio NVCR

Market value divided by the book value of the company's net assets, since 2015.

Today, Nov 2, 2026
4.4×
10-year median
16.6×
Against its 10-year history
15th
percentile: 0 is its lowest day, 100 its highest
10-year range
3.0× to 63.1×
Peer median
4.2×

NovoCure's price to book ratio is 4.4× as of Nov 2, 2026.

That is below its ten-year median of 16.6×, lower than on 85% of days in the last ten years.

Over that time it ranged from 3.0× in Nov 2023 to 63.1× in Feb 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 4.2×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.4×3.3×6.3×
20254.4×3.6×9.1×
20249.2×3.6×10.0×
20234.1×3.0×25.7×
202217.3×13.9×22.3×
202118.9×18.9×63.1×
202057.4×24.5×57.4×
201945.5×27.2×57.9×
201826.6×15.3×43.4×
201715.5×3.4×16.7×
20164.3×2.8×13.9×
201515.4×15.2×19.1×

Against its peers

Companies in Medical - Instruments & Supplies nearest NovoCure's size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on NovoCure

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.